Pharmaceutical

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

Jun 17, 2025 - 06:00
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

Read the original article

Tags:

Previous Article

Ethris and Thermo Fisher partner on mRNA solutions

Next Article

NICE approves GSK’s belantamab mafodotin for blood cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi and Regeneron report results from two Phase III trials of COPD treatment

Sanofi and Regeneron report results from two Phase III ...

Jun 3, 2025

Black people are more likely to be physically restrained in emergency rooms, study finds

Black people are more likely to be physically restraine...

Sep 26, 2023

Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab

Signal: AbbVie ends multi-million dollar cancer drug de...

Sep 25, 2023